Physician profile
Varsha S Taskar
NPI 1831173426
$4,945.41
in general payments reported to CMS, 2019-2025
39 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $426 · 2021: $445 · 2022: $1,395 · 2023: $842 · 2024: $509 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $75.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.87 |
| Education | $75.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $746.31 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $595.41 | 2019-2023 | Arikayce |
| United Therapeutics Corporation | $532.09 | 2022-2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $381.29 | 2022-2024 | Uptravi, Opsumit |
| Jazz Pharmaceuticals INC. | $233.80 | 2022-2023 | Xywav |
| Chiesi USA, INC. | $218.12 | 2020-2023 | Bronchitol |
| Inspire Medical Systems, INC. | $205.45 | 2022 | |
| Ani Pharmaceuticals, INC. | $186.61 | 2023-2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $182.98 | 2023-2025 | Winrevair |
| Harmony Biosciences LLC | $178.50 | 2021-2022 | |
| Inari Medical, INC. | $172.15 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mylan Specialty L.P. | $140.68 | 2019-2024 | Yupelri, Tobi Podhaler |
| Vertex Pharmaceuticals Incorporated | $134.87 | 2022-2025 | Trikafta |
| Boston Scientific Corporation | $131.74 | 2022 | |
| Glaxosmithkline, LLC. | $114.22 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $105.24 | 2020-2024 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Medtronic Vascular, INC. | $91.62 | 2020 | |
| Genzyme Corporation | $71.97 | 2025 | |
| Baxter Healthcare | $66.77 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Shionogi INC | $62.32 | 2022-2023 | Fetroja |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Abbvie INC. | $40.06 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $30.67 | 2024-2025 | Fasenra |
| La Jolla Pharmaceutical Company | $30.48 | 2023 | Giapreza |
| Alcresta Therapeutics, INC. | $29.46 | 2025 | Relizorb |
| Shire North American Group INC | $25.41 | 2019 | |
| Sandoz INC. | $23.09 | 2022 | |
| Viatris Specialty LLC | $22.95 | 2025 | Tobi Podhaler |
| Amgen INC. | $22.12 | 2022 | |
| Philips North America LLC | $21.56 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.98 | 2023 | Ultomiris |
| Novo Nordisk INC | $16.89 | 2023 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $16.80 | 2022 | |
| Aurinia Pharma U.S., INC. | $13.63 | 2024 | Lupkynis |
| Janssen Pharmaceuticals, INC | $13.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.61 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varsha Taskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.